HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) in a research report report published on Wednesday, Marketbeat.com reports. HC Wainwright currently has a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.26) EPS, Q1 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($1.19) EPS.
A number of other equities research analysts have also recently weighed in on ABEO. Cantor Fitzgerald cut their price objective on shares of Abeona Therapeutics from $28.00 to $21.00 and set an overweight rating on the stock in a research note on Thursday, May 16th. Stifel Nicolaus assumed coverage on shares of Abeona Therapeutics in a research report on Thursday, May 30th. They set a buy rating and a $21.00 price target on the stock. Finally, StockNews.com upgraded shares of Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 13th.
Read Our Latest Report on Abeona Therapeutics
Abeona Therapeutics Price Performance
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). As a group, equities analysts anticipate that Abeona Therapeutics will post -1.81 EPS for the current year.
Institutional Investors Weigh In On Abeona Therapeutics
A number of large investors have recently made changes to their positions in ABEO. Acadian Asset Management LLC purchased a new position in shares of Abeona Therapeutics during the first quarter valued at $91,000. Jump Financial LLC purchased a new position in Abeona Therapeutics during the 4th quarter valued at about $199,000. Bank of New York Mellon Corp increased its holdings in shares of Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 2,434 shares during the period. Simplify Asset Management Inc. purchased a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $1,732,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
- Five stocks we like better than Abeona Therapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 8/12 – 8/16
- Using the MarketBeat Dividend Tax Calculator
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.